Markets

medicine

Personalized Medicine Market, 2029 | Markets Insider

DUBLIN, Nov. 11, 2020 /PRNewswire/ — The “Personalized Medicine – Scientific & Commercial Aspects” report from Jain PharmaBiotech has been added to ResearchAndMarkets.com’s offering.

The concept of personalized medicine described in this report remains remains the best way to integrate new technologies such as nanobiotechnology for improving healthcare.

Increase in efficacy and safety of treatment by individualizing it has benefits in financial terms. Information is presented to show that personalized medicine will be cost-effective in healthcare systems. For the pharmaceutical companies, segmentation of the market may not leave room for conventional blockbusters but smaller and exclusive markets for personalized medicines would be profitable. Marketing opportunities for such a system are described with market estimates from 2019-2029.

Profiles of 298 companies involved in developing technologies for personalized medicines, along with 583 collaborations are included.
The aim of personalized medicine or individualized treatment is to match the right drug to the right patient and, in some cases, even to design the appropriate treatment for a patient according to his/her genotype. This report describes the latest concepts of development of personalized medicine based on pharmacogenomics, pharmacogenetics,pharmacoproteomics, and metabolomics.

Basic technologies of molecular diagnostics play an important role, particularly those for single nucleotide polymorphism (SNP) genotyping. Biomarkers play an important role in personalized medicine. Diagnosis is integrated with therapy for selection of treatment as well for monitoring the results. There is emphasis on early detection and prevention of disease in modern medicine. Biochip/microarray technologies and next generation sequencing are also important.

Pharmacogenetics, the study of influence of genetic factors on drug action and metabolism, is used for predicting adverse reactions of drugs. Several enzymes are involved in drug metabolism of which the most important ones are those belonging to the family of cytochrome P450. The knowledge of the effects of polymorphisms of genes for the enzymes is applied in drug discovery and development as well as in clinical use of drugs. Cost-effective methods for genotyping are being developed and it would be desirable to include this information in the patient’s record for the guidance of the physician to individualize the treatment.

Pharmacogenomics, a term that overlaps with pharmacogenetics but is distinct, deals with the application of genomics to drug discovery and development. It involves the mechanism of action of drugs on cells as revealed by gene expression patterns. Pharmacoproteomics is an important contribution to personalized medicine as it is a more functional representation of patient-to-patient variation than that provided by genotyping.A ‘pharmacometabonomic’ approach to personalizing drug treatment is also described.

Biological therapies such as those which use patient’s own cells are considered to be personalized medicines. Vaccines are prepared from individual patient’s tumor cells. Individualized therapeutic strategies using monoclonal bodies can be directed at specific genetic and immunologic targets. Ex vivo gene therapy involves the genetic modification of the patient’s cells in vitro, prior to reimplantation of these cells in the patient’s body.

Various technologies are integrated to develop personalized therapies for specific therapeutic areas described in the report. Examples of this are

Read More
medicine

Igentify, Genosity cooperate to bring precision medicine to all markets

Israeli digital health company Igentify will cooperate with US-based biotech firm Genosity to deliver the next step in precision medicine to all markets. Precision medicine is a new trend in the healthcare industry, Igentify director of partnerships Yael Furman told The Jerusalem Post.  

“Imagine a person suffering from a headache,” she said, “that person would take an aspirin. The drug is produced for all people who suffer from a headache. Yet in some cases, such as cancer, it’s extremely useful to know the genetic profile of the patient as that would make the treatment a lot more effective.” 

This still means mass-produced drugs for the most common genetic types in a given population, but perhaps drugs will eventually be made for the unique individual who needs them.  

The trend is coupled with other leaps and bounds medicine is going through thanks to big data and the digital age. For example, a woman who has a genetic likelihood to suffer from breast cancer could get digital “pushes” in the form of texts and emails that will remind her to get tested. Better and more frequent testing saves lives.  

“People see our animated videos and forget the mountain of work that goes into genetic research,” Igentify founder and CEO Dr. Doron Behar explains.  

“The videos are important because we want people to understand what the genetic test is, what will happen to their data, and to give their informed consent. Yet that is just the last step – what we do much more,” he said.

“There are only 7,000 genetic counselors in the world today,” Behar said. “This is a huge bottle neck that prevents people from having access to, and benefiting from, their own genetic data. Machine learning can take some of that burden off and deliver the service to more [people]. ”   

IGENTIFY HELPS medical service providers to set up the complex systems needed to decipher such data – from cheek swabs to lab robots to machine learning that is able to scan most possibilities of human genetic material creating a new life.   

“We use cheek swabs because they’re easier to do than blood samples and give us cells from the human cheek,” he explains, “it’s not the spit we’re after, it’s cells. Each cell has your entire genome in it.”  

If a man and a woman are thinking about having a baby together and if they have access to a genetic testing service, it could predict what is the likelihood of the yet-unborn child having a genetic disease based on the genetic analysis of both parents.  

A woman could use a simple cheek swab to learn if she is at risk of suffering from breast cancer. The information is presented in a friendly and easy to understand animated video that has a lot of planning behind it.   

“We’re able to offer this service not just in other languages but also with different avatars,” Behar pointed

Read More
medicine

Global Personalized Medicine Markets Report 2020: Focus on Scientific Basis & Technologies and Markets & Companies

The “Personalized Medicine – Scientific & Commercial Aspects” report from Jain PharmaBiotech has been added to ResearchAndMarkets.com’s offering.

The concept of personalized medicine described in this report remains the best way to integrate new technologies such as nanobiotechnology for improving healthcare.

Increase in efficacy and safety of treatment by individualizing it has benefits in financial terms. Information is presented to show that personalized medicine will be cost-effective in healthcare systems. For the pharmaceutical companies, segmentation of the market may not leave room for conventional blockbusters but smaller and exclusive markets for personalized medicines would be profitable. Marketing opportunities for such a system are described with market estimates from 2019-2029.

Profiles of 298 companies involved in developing technologies for personalized medicines, along with 583 collaborations are included.

The aim of personalized medicine or individualized treatment is to match the right drug to the right patient and, in some cases, even to design the appropriate treatment for a patient according to his/her genotype. This report describes the latest concepts of development of personalized medicine based on pharmacogenomics, pharmacogenetics,pharmacoproteomics, and metabolomics.

Basic technologies of molecular diagnostics play an important role, particularly those for single nucleotide polymorphism (SNP) genotyping. Biomarkers play an important role in personalized medicine. Diagnosis is integrated with therapy for selection of treatment as well for monitoring the results. There is emphasis on early detection and prevention of disease in modern medicine. Biochip/microarray technologies and next generation sequencing are also important.

Pharmacogenetics, the study of influence of genetic factors on drug action and metabolism, is used for predicting adverse reactions of drugs. Several enzymes are involved in drug metabolism of which the most important ones are those belonging to the family of cytochrome P450. The knowledge of the effects of polymorphisms of genes for the enzymes is applied in drug discovery and development as well as in clinical use of drugs. Cost-effective methods for genotyping are being developed and it would be desirable to include this information in the patient’s record for the guidance of the physician to individualize the treatment.

Pharmacogenomics, a term that overlaps with pharmacogenetics but is distinct, deals with the application of genomics to drug discovery and development. It involves the mechanism of action of drugs on cells as revealed by gene expression patterns. Pharmacoproteomics is an important contribution to personalized medicine as it is a more functional representation of patient-to-patient variation than that provided by genotyping.A ‘pharmacometabonomic’ approach to personalizing drug treatment is also described.

Biological therapies such as those which use patient’s own cells are considered to be personalized medicines. Vaccines are prepared from individual patient’s tumor cells. Individualized therapeutic strategies using monoclonal bodies can be directed at specific genetic and immunologic targets. Ex vivo gene therapy involves the genetic modification of the patient’s cells in vitro, prior to reimplantation of these cells in the patient’s body.

Various technologies are integrated to develop personalized therapies for specific therapeutic areas described in the report. Examples of this are genotyping for drug resistance in HIV

Read More
medicine

Sports Medicine Device Market Insights (2020 to 2025) – Analysis and Forecast for the Global and Chinese Markets – Press Release

Dublin, Nov. 02, 2020 (GLOBE NEWSWIRE) — The “Sports Medicine Device Market Insights 2020, Analysis and Forecast Global and Chinese Market to 2025, by Manufacturers, Regions, Technology, Product Type” report has been added to ResearchAndMarkets.com’s offering.

This report is a professional and in-depth study on the current state of the global Sports Medicine Device market with a focus on the Chinese market. The report provides key statistics on market of Sports Medicine Device. It is a valuable source of guidance and direction for companies and individuals interested in Sports Medicine Device industry.

Key points of Sports Medicine Device Market Report:
1. The report provides a basic overview of Sports Medicine Device industry including: definition, applications and manufacturing technology.
2. The report explores Global and Chinese major players in Sports Medicine Device market. In this part, the report presents the company profile, product specifications, capacity, production value, and 2015-2020 market shares for each company.
3. The report depicts the global and Chinese total Sports Medicine Device market including: capacity, production, production value, cost/profit, supply/demand and Chinese import/export, by statistical analysis.
4. The global Sports Medicine Device market is further divided by company, by country, and by application/type for the competitive landscape analysis.
5. The report then estimates 2020-2025 development trends, analyse upstream raw materials, downstream demand, and current market dynamics of Sports Medicine Device market.
6. The report makes some important proposals for a new project of Sports Medicine Device Industry before evaluating its feasibility.
7. Overall, the report provides an in-depth insight of 2015-2025 global and Chinese Sports Medicine Device market covering all important parameters.

Main Parameters for this report:

Type Segment:

Companies Covered:

  • Arthrex
  • Smith & Nephew
  • Stryker
  • Depuy Synthes/Johnson & Johnson
  • Zimmer Biomet
  • Karl Storz
  • Conmed
  • Wright
  • Medshape
  • Valeris
  • Rog
  • Aceosteo
  • Asco Medical
  • Atlas Surgical
  • Auxein
  • Biotek
  • Bonetech Medisys
  • CHM
  • Egifix
  • Forerunner
  • Fxorthopedi
  • Gesco Medical
  • GPC Medical Ltd
  • Green Surgical
  • Griphorto
  • Hardik International
  • HIBS
  • Innomed Solutions
  • Jeil Medical
  • Jiangsu Bai De Medical Instrument
  • Marapole
  • Matrix
  • Medgal
  • Microport
  • Miraclus
  • Narang
  • Naton Group
  • Nebula

Key Topics Covered:

1.: Introduction of Sports Medicine Device Industry
1.1 Brief Introduction of Sports Medicine Device
1.2 Development of Sports Medicine Device Industry
1.3 Status of Sports Medicine Device Industry

2.: Manufacturing Technology of Sports Medicine Device
2.1 Development of Sports Medicine Device Manufacturing Technology
2.2 Analysis of Sports Medicine Device Manufacturing Technology
2.3 Trends of Sports Medicine Device Manufacturing Technology

3.: Analysis of Global Key Manufacturers
3.1 Arthrex
3.1.1 Company Profile
3.1.2 Product Information
3.1.3 Capacity Production Price Cost Production Value
3.1.4 Contact Information
3.2 Smith & Nephew
3.2.1 Company Profile
3.2.2 Product Information
3.2.3 Capacity Production Price Cost Production Value
3.2.4 Contact Information
3.3 Stryker
3.3.1 Company Profile
3.3.2 Product Information
3.3.3 Capacity Production Price Cost Production Value
3.3.4 Contact Information
3.4 Depuy Synthes/Johnson & Johnson
3.4.1 Company Profile
3.4.2 Product Information
3.4.3 Capacity Production Price Cost Production Value
3.4.4 Contact Information
3.5 Zimmer Biomet
3.5.1 Company Profile
3.5.2 Product Information
3.5.3 Capacity Production Price Cost Production Value
3.5.4 Contact Information
3.6 Karl

Read More
medicine

After Final Debate, Both Candidates Need to Embrace Markets in Medicine

|

Posted: Oct 24, 2020 12:01 AM

The opinions expressed by columnists are their own and do not necessarily represent the views of Townhall.com.

Safe to say, not too many Americans will change who they are voting for after last night’s debate. Unlike the previous debate, however, the candidates had some interesting things to say about policy. Biden accused Trump of trying to strip away healthcare coverage for more than 20 million Americans by attempting to repeal the Affordable Care Act (ACA; aka Obamacare). Meanwhile, Trump accused Biden of trying to eliminate private insurance for more than 200 million Americans.

The expensive truth is that both candidates are pedaling big-government policies that will hike prices and decrease patient choice if enacted. Biden and Trump may not see eye to eye on much, but they must agree on expanding choice and competition in the U.S. healthcare system.

Slated to cost an estimated $750 billion in extra spending over the next 10 years, Biden’s healthcare plan would be astoundingly expensive. Biden’s “Obamacare on steroids” approach would significantly increase subsidies for state healthcare exchanges and set up a “public option” to fill in present-day gaps in health coverage. As policy experts pointed out a decade ago during the original debate over Obamacare, it’d be next to impossible to design a public option in a way that wouldn’t drive private insurers out of business. After all, this taxpayer-funded entity could set healthcare premium prices far lower than any company ever could. In the private sector, setting prices below healthcare and administrative costs will result in near-instant bankruptcy.

A government-run organization, though, could simply tap taxpayers for a bailout if their prices prove to be too low. But even this slow-motion “public option” disaster would be a libertarian pipedream compared to what we’d actually get under a Biden administration. The former Vice President doesn’t operate in a policy vacuum, and policy advisors close to him such as running mate Sen. Kamala Harris (D-Calif.), are likely to exert significant influence on any Biden agenda. Before dropping out of the race and endorsing Biden, Harris supported a Medicare for All plan that envisioned, “10-year transition plan away from the current healthcare system, at the end of which, “every American will be a part of this new Medicare system. They will get insurance either through the new public Medicare plan or a Medicare plan offered by a private insurer within that system.” This private component is supposed to be modeled after Medicare Advantage, which consists of plans subscribed to by seniors and sponsored (at least partially) by private insurance companies.

The Medicare Advantage program does offer some improvements relative to traditional Medicare plans, since private companies can compete with one another albeit in a strictly regulated framework. But, make no mistake, these “private” Medicare plans are still funded by taxpayers and private sponsors are strictly curtailed in what healthcare options they can offer patients. If Harris gets her way or at least has significant input in “Bidencare,” private

Read More
fitness

Snap Fitness Reacquires UK and Ireland Markets from Master Developer

International fitness group continues commitment to #OneTeam mentality by investing in the Snap Fitness team, infrastructure and franchise support with more than 100 clubs across Europe

CHANHASSEN, Minnesota, Oct. 21, 2020 /PRNewswire/ — Snap Fitness, the world’s premier 24/7 fitness concept creating happy and healthy lifestyles for its members, today announced the reacquisition of the UK and Ireland market from its Master Developer.

As part of the global fitness brand’s #OneTeam initiative, which strives to support its team members and franchisees running businesses amidst COVID-19 guidelines, Snap Fitness is continuing to invest internally within the quickly growing UK market. Investments will include infrastructure development, club growth, franchise support and innovative product and technology offerings.

Jon Cottam, previously Managing Director, Europe of Lift Brands (Snap Fitness parent company), will now serve as CEO, EMEA, as the company builds and develops its programs across Europe and other territories for Snap Fitness and sister fitness concept 9Round. Cottam, who has been with Lift Brands since 2018, is an industry veteran in fitness management.

“We have some incredible growth opportunities across our newly reacquired market,” said Alison McElroy, President, International & Chief Legal Officer at Lift Brands global. “I know Jon will continue to excel in this new leadership role, managing the charge for both brands as we continue to grow and build business across EMEA.”

“We are proud of the work we have done so far to support our small business owners,” said Ty Menzies, global CEO of Lift Brands. “We will continue to look for additional opportunities to invest in operations, connecting our people – both locally and globally – as we help our Snap Fitness community weather the storm of COVID-19 together.”

In 2020, Snap Fitness surpassed 100 clubs in Europe and opened five new clubs across the globe in September alone, with the first-ever Japan location set to open in November.

For more information on Snap Fitness, visit the website at www.snapfitness.com.

About Snap Fitness:
Snap Fitness is the world’s most rewarding 24/7 fitness concept with over 2,000 clubs open or scheduled for development in over 20 countries. Snap Fitness offers members the opportunity to see real results. We provide the latest in fitness technology, diverse workout options, personal training, and the most supportive fitness community around the globe. A major fitness brand since 2003, we continue to evolve sustainably along with key fitness trends to provide results for every body!

About Lift Brands:
Lift Brands is a leading innovator in the fitness industry as the parent brand to several fitness franchises and fitness brands worldwide including Snap Fitness, YogaFit Studios Franchise, Fitness On Demand and is a minority partner in 9Round global franchise. With over 1 million members and 2,000 locations open or scheduled for development and locations in over 26 countries, Lift Brands delivers results through the most rewarding fitness experiences in the world and changes lives daily. For more information on Lift Brands, please visit www.liftbrands.com.

Logo – https://mma.prnewswire.com/media/1135113/Snap_Fitness_Logo.jp

Related

Read More
health

Micro Injection Molding: Global Markets

Report Scope: Micro-molding is a dedicated manufacturing and production process which yields exceptional precision in small components and parts which have micron tolerances. The process starts with creating a mold that has a cavity like the shape of the desired part.

New York, Oct. 20, 2020 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Micro Injection Molding: Global Markets” – https://www.reportlinker.com/p05977634/?utm_source=GNW

Various types of molds such as resin or thermoplastics are injected at a high speed into the cavity to create the component or part precisely. Micro injection molding is widely used in medical devices, healthcare devices, implants, surgical instruments, various automotive parts, electronic parts, small machine parts and other industries.

This report offers insight on the types of polymers used during the molding process and is segmented by type –
– Polyethylene (PE).
– Polycarbonate (PC).
– Polyether ether ketone (PEEK).
– Others (polyoxymethylene, liquid crystal polymer, polymethylmethacrilate, polyamide).

This micro injection molding market report offers insights on the end-use applications where these parts are used and is segmented by end user, including –
– Medical and healthcare.
– Automotive.
– Telecom fiber optics.
– Micro drive systems and controls.
– Others (aerospace, defense).

The market has been defined by segments and regions and further bifurcated into regions and countries. In addition, the report offers comprehensive factors, including drivers, restraints, challenges and opportunities, which provide an overall picture of global trends and market opportunities.

Report Includes:
– 39 tables
– Comprehensive overview of the global markets for micro injection molding — a key technology for the micro manufacturing of high-precision small components and parts
– Analyses of the global market trends, with data corresponding to market size for 2019, estimates for 2020, and projections of compound annual growth rates (CAGRs) through 2025
– Latest information on market opportunities, prospects and threats, new and upcoming technologies, merger and acquisition deals, and other developments in the micro injection molding market
– Country specific data and analysis for the U.S., Canada, Mexico, Germany, Italy, UK, India, China, Brazil, Middle East and Africa
– Assessment of the actual market size, market estimation and forecast, and market share analysis of micro injection molding market based on type of polymer material, end-use and geographical region
– Competitive landscape of the market leading participants, their company share analysis, market positioning and research priorities
– Detailed profiles of the major listed companies, including Accumold, Microsystems U.K., Microdyne Plastics Inc., MTD Micro Molding, Rapidwerks Inc., and Sumitomo (SHI) Demag Plastics Machinery GmbH

Summary:
The global micro injection molding market was valued at REDACTED in 2019 and is estimated to reach REDACTED in 2025, growing with a CAGR of REDACTED during the forecast period.Micro injection molding is an extremely specialized manufacturing process which is used to produce small, highprecision metal and thermoplastic components and parts with micron tolerances.

Micro molding starts with a mold cavity in the structure of the desired part, where resin or thermoplastic is injected with desired speed into the hollow cavity, producing the

Read More